Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.

ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating disorder that results in frequent exacerbations and impacts quality of life. It represents a growing burden of health care cost, both from societal and economic perspectives. Short- and long-acting bronchodilators remain the mainstay of therapy in COPD patients. New fixed-dose combination inhalers with novel pharmacological combinations of long-acting β2-agonists and muscarinic antagonists and delivered once-daily through a variety of devices are currently being developed and licensed for the treatment of COPD. There is mounting research suggesting that combining a fixed dose of a β2-agonist and a muscarinic antagonist achieves better bronchodilation and clinical outcomes compared with either agent alone. These onc

SUBMITTER: Muruganandan S 

PROVIDER: S-EPMC4476436 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature